Trials / Active Not Recruiting
Active Not RecruitingNCT03902184
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 170 (actual)
- Sponsor
- Innate Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IPH4102 | Patients will receive a flat dose of 750mg |
Timeline
- Start date
- 2019-05-22
- Primary completion
- 2023-10-31
- Completion
- 2026-01-31
- First posted
- 2019-04-03
- Last updated
- 2024-11-08
Locations
53 sites across 8 countries: United States, Austria, Belgium, France, Germany, Italy, Poland, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03902184. Inclusion in this directory is not an endorsement.